The Medical Treatment of New-Onset Peripartum Cardiomyopathy: A Systematic Review of Prospective Studies

详细信息    查看全文

• 作者：Olivier Desplantie ; MDCM^a ; Maxime Tremblay-Gravel ; MD ; MSc^a ; Robert Avram ; MD^a ; Guillaume Marquis-Gravel ; MD ; MSc^a ; Anique Ducharme ; MD ; MSc^b ; E. Marc Jolicoeur ; MD ; MSc ; MHS ; FRCP-C ; FACC ; FSCAI^a ; ^b ; ^{marc.jolicoeur@icm-mhi.org" class="auth_mail" title="E-mail the corresponding author} ; for the BRO-HF Initiative Investigators
• 刊名：Canadian Journal of Cardiology
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：31
• 期：12
• 页码：1421-1426
• 全文大小：448 K

文摘

Peripartum cardiomyopathy (PPCM) is a rare disorder with potentially fatal consequences, which occurs mainly in previously healthy women. The aetiology of PPCM remains unknown and various pathologic mechanisms have been proposed, including immune-mediated injuries and impaired response to oxidative stress and inflammatory cytokines. Several therapies have been studied, but few have been validated in a well-designed randomized controlled trial.

Methods

In the present study we sought to review the medical treatment intended for acute PPCM. To this end, we performed a systematic review of the literature of randomized and nonrandomized prospective clinical studies.

Results

We identified 2 randomized controlled trials that evaluated the dopamine agonist bromocriptine and the inotrope levosimendan, respectively, and 1 nonrandomized study that evaluated the nonselective phosphodiesterase inhibitor pentoxifylline. We reviewed the pathophysiological, pharmacological, and clinical properties for each treatment option identified. Bromocriptine and pentoxifylline both improved left ventricular systolic function and patient-oriented clinical end points and levosimendan did not improve mortality or echocardiographic findings of PPCM.

Conclusions

In this review we identified bromocriptine and pentoxifylline, but not levosimendan, as potentially useful agents to improve left ventricle function and outcomes in PPCM.